Infantile Hemangiomas: When to Watch, When to Treat, and How to Use Propranolol Safely
Clinical Practice Update — Risk Classification, Early Referral, Propranolol Initiation, Topical Timolol, Associated Syndromes, and Treatment Timing
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Identification and risk classification of infantile hemangiomas, indications for active treatment versus observation, oral propranolol as first-line systemic therapy, topical timolol for superficial lesions, management of ulcerated IH, PHACE and LUMBAR syndrome evaluation, and surgical/laser options
- Target Audience
- General paediatricians, family physicians, paediatric dermatologists, paediatric surgeons, neonatal nurses, residents
- Setting
- Primary care, outpatient paediatrics, paediatric dermatology clinics, neonatal units
- Source Evidence
- •AAP Clinical Practice Guideline — Management of Infantile Hemangiomas (Pediatrics, 2019)
- •BSPD Consensus Guidelines — Oral Propranolol for Proliferating Infantile Haemangiomas (BJD, 2018)
- •US Multidisciplinary Consensus Conference — Initiation and Use of Propranolol for Infantile Hemangioma (Pediatrics, 2013)
- •PHACE Syndrome Consensus — Diagnosis and Care Recommendations (J Pediatr, 2016)
- •Olsen et al. — Safety of Oral Propranolol in PHACE Syndrome (JAMA Dermatol, 2020)
Key Clinical Takeaways
Infantile hemangiomas are the most common benign tumour of infancy, affecting roughly 4–5% of infants. Most are harmless and self-resolve. The clinical challenge is identifying the minority that require early, active treatment to prevent permanent complications.
- 1Most infantile hemangiomas are low-risk and self-resolve — educate families about the natural history of proliferation (peaking at 1–3 months) followed by slow involution → Natural History
- 2Classify every infantile hemangioma as high-risk or low-risk based on location, size, and potential for complications — high-risk lesions require specialist referral by age 1 month → Risk Classification
- 3Oral propranolol is the first-line systemic treatment for high-risk IH — pooled data show a mean expected clearance rate of approximately 95%, and it is FDA-approved for this indication → Propranolol
- 4Start propranolol ideally before age 5 months (peak of proliferation) — earlier treatment produces better cosmetic and functional outcomes → Treatment Timing
- 5Topical timolol maleate is an option for thin, superficial hemangiomas where systemic therapy is not warranted → Topical Therapy
- 6Think PHACE syndrome with any large segmental facial hemangioma — investigate with MRI/MRA and echocardiography before or shortly after starting propranolol → PHACE Syndrome
- 7Screen for hepatic hemangiomas with ultrasound if the infant has 5 or more cutaneous lesions — hepatic IH can cause high-output cardiac failure and consumptive hypothyroidism → Multifocal IH
- 8Do not routinely image hemangiomas — imaging is only needed when the diagnosis is uncertain, structural abnormalities are suspected, or there are ≥5 cutaneous IH → Imaging
- 9Counsel families that the psychosocial impact of a facial hemangioma can be significant — visible lesions cause parental distress and may warrant earlier treatment even without functional impairment → Psychosocial Impact
Which Hemangiomas Should Concern You?
The traditional “wait and see” approach is appropriate for most infantile hemangiomas. However, the AAP 2019 guideline fundamentally shifts the emphasis: high-risk lesions must be identified early and referred promptly, ideally by age 1 month, because rapid proliferation peaks between 1 and 3 months and most growth is complete by 5 months.
Any IH that threatens the child's life (e.g., airway compromise, hepatic overload), risks impairing function or causing ulceration, raises concern for an associated syndrome such as PHACE or LUMBAR, or is likely to leave lasting cosmetic damage should be classified as high-risk and managed accordingly.
Strong Rec Low Evidence AAP 2019Refer high-risk infantile hemangiomas to a hemangioma specialist as soon as possible, ideally by age 1 month. Growth is most rapid between 1 and 3 months; treatment started before or during this window achieves the best outcomes.
Strong Rec Low Evidence AAP 2019Counsel parents and caregivers about the natural history of infantile hemangiomas — proliferative phase (birth to ~5 months), plateau, and slow involution (months to years). Explain that while most resolve, more than half (55–69% in referral populations) leave residual skin changes (telangiectasia, fibrofatty tissue, skin redundancy) even after complete involution.
Strong Rec Low Evidence AAP 2019Identifying High-Risk Infantile Hemangiomas: Organised by Clinical Urgency
| Location | Why It Matters | What Can Go Wrong | Recommended Action | Urgency |
|---|---|---|---|---|
| Beard distribution | Subglottic airway hemangioma risk | Life-threatening airway obstruction | Low threshold for direct laryngoscopy; early propranolol | Immediate |
| Multiple (≥5 cutaneous) | Hepatic hemangioma risk | High-output cardiac failure, consumptive hypothyroidism | Abdominal ultrasound; thyroid function; cardiac assessment | Immediate |
| Periorbital | Amblyopia, astigmatism, visual axis obstruction | Even a small IH near the eye can cause irreversible visual loss | Urgent ophthalmology and IH specialist referral | Immediate |
| Large segmental facial | PHACE syndrome association | Posterior fossa, cerebrovascular, cardiac, and eye anomalies | MRI/MRA brain + echocardiography BEFORE or shortly after propranolol | Within days |
| Lumbosacral/perineal | LUMBAR syndrome association | Spinal dysraphism, urogenital anomalies, tethered cord | MRI spine; urology assessment if midline | Within days |
| Lip | High ulceration risk; feeding interference | Ulceration causes pain and scarring at a cosmetically sensitive site | Active treatment; wound care if ulcerated | Within 1–2 weeks |
| Nasal tip (“Cyrano nose”) | Permanent nasal cartilage distortion | Disfigurement persists even after IH involutes | Early systemic treatment to prevent structural damage | Within 1–2 weeks |
| Ear | Permanent auricular deformity; risk of scarring | Disfigurement of ear contour; if ulcerated, profuse bleeding on scalp | Active treatment; specialist referral | By age 1 month |
| Breast (female infants) | Permanent breast development changes | Breast asymmetry or nipple contour changes | Active treatment to prevent long-term deformity | By age 1 month |
How Should You Treat a High-Risk Infantile Hemangioma?
Oral propranolol has transformed the management of infantile hemangiomas since its serendipitous discovery in 2008. It is now the universally recommended first-line systemic therapy across all major guidelines — AAP, European, UK, and Australasian. Understanding how to initiate it safely is essential for any clinician managing infants.
Prescribe oral propranolol as the first-line systemic agent for infantile hemangiomas requiring active treatment. Target dose: 2–3 mg/kg/day divided into two or three doses, administered with or immediately after feeds to reduce hypoglycaemia risk.
Strong Rec High Evidence AAP 2019 BSPD 2018Start low and go slow: begin propranolol at 1 mg/kg/day, then increase to the full 2–3 mg/kg/day target over one to two weeks. For otherwise healthy infants beyond 5 weeks corrected gestational age, outpatient initiation is reasonable — check heart rate and blood pressure for two hours after the very first dose. Younger infants or those with comorbidities (cardiac disease, PHACE with cerebrovascular anomalies) should be admitted for monitored initiation.
Moderate Rec Moderate Evidence AAP 2019 FDA LabelFamilies need to understand that propranolol and feeding go hand-in-hand — every dose should follow a feed, never be given on an empty stomach. If the infant is unwell, vomiting, or feeding poorly for any reason, propranolol should be withheld until normal intake resumes. Hypoglycaemia is the most clinically significant safety concern and is almost always linked to fasting or inadequate caloric intake. Other adverse effects to discuss include sleep disturbance, cool extremities, and rarely bronchospasm.
Strong Rec Low Evidence AAP 2019 BSPD 2018Consider topical timolol maleate 0.5% gel-forming solution for thin, superficial infantile hemangiomas that are not in high-risk locations and do not warrant systemic therapy. Apply one drop two to three times daily to the lesion surface. Systemic absorption is possible, so monitor for bradycardia in small or premature infants.
Moderate Rec Moderate Evidence AAP 2019Consider oral prednisolone/prednisone (2–3 mg/kg/day) as a second-line systemic agent if propranolol is contraindicated (e.g., reactive airway disease, significant bradycardia) or if the response to propranolol is inadequate. Longer courses carry typical steroid side effects.
Moderate Rec Moderate Evidence AAP 2019Clinical Decision Pathway
Evidence in Context
Where All Guidelines Agree
The AAP (2019), European consensus, BSPD (2018), and Australasian guidelines are unanimous: oral propranolol is the first-line systemic treatment for problematic IH, at a dose of 2–3 mg/kg/day. All agree on the importance of early identification, referral by 1 month of age for high-risk lesions, and pre-treatment cardiac assessment for infants with suspected PHACE syndrome. All recommend active observation with photographic documentation for low-risk IH.
Where They Differ: Propranolol Initiation Setting
The 2013 US consensus conference and the European expert consensus recommend inpatient initiation for infants under 8 weeks corrected age or with comorbidities. The FDA-approved label for Hemangeol (cited in the AAP 2019 guideline) sanctions outpatient initiation for healthy infants over 5 weeks corrected age with heart rate and blood pressure monitoring for 2 hours after the first dose. The BSPD 2018 guideline similarly supports outpatient initiation in healthy infants with appropriate monitoring. Both approaches are reasonable; the choice depends on local resources and the infant's clinical profile.
Atenolol as an Alternative: Emerging Evidence
Atenolol, a selective beta-1 blocker that does not cross the blood-brain barrier, has shown similar efficacy to propranolol in several studies and meta-analyses, with potentially fewer sleep disturbances and pulmonary side effects. However, it is not yet FDA-approved for this indication, and the evidence base is smaller than for propranolol. Current guidelines do not yet recommend atenolol as a first-line alternative, but it is increasingly used off-label when propranolol causes intolerable sleep disruption or bronchospasm.
Propranolol in PHACE: Safe With Precautions
Early concerns that propranolol could cause stroke in PHACE patients by reducing cerebral perfusion have not been borne out. A 2020 multicentre retrospective cohort study (Olsen et al.) of 76 PHACE patients treated with propranolol reported no serious adverse events, including no strokes, transient ischaemic attacks, or cardiovascular events. However, careful pre-treatment imaging (MRI/MRA) and cardiology assessment remain essential. For infants with confirmed cerebrovascular anomalies, propranolol should be started at a lower dose (0.5 mg/kg/day in three divided doses) under neurology co-management, with slow escalation.
What We Still Don't Know
References
- 1.Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics. 2019;143(1):e20183475. doi:10.1542/peds.2018-3475
- 2.Solman L, Glover M, Beattie PE, et al. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines. Br J Dermatol. 2018;179(3):582–589. doi:10.1111/bjd.16779
- 3.Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and Use of Propranolol for Infantile Hemangioma: Report of a Consensus Conference. Pediatrics. 2013;131(1):128–140. doi:10.1542/peds.2012-1691
- 4.Garzon MC, Epstein LG, Heyer GL, et al. PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations. J Pediatr. 2016;178:24–33.e2. doi:10.1016/j.jpeds.2016.07.054
- 5.Giachetti A, Díaz MS, Boggio P, et al. Early propranolol treatment of infantile hemangiomas improves outcome. An Bras Dermatol. 2023;98(3):310–315. doi:10.1016/j.abd.2022.04.008
- 6.Olsen GM, Hansen LM, Stefanko NS, et al. Evaluating the Safety of Oral Propranolol Therapy in Patients With PHACE Syndrome. JAMA Dermatol. 2020;156(2):186–190. doi:10.1001/jamadermatol.2019.3382
How to Read the Evidence Tags
Every recommendation carries two tags. These are Medaptly's own simplified interpretations for educational clarity.
Recommendation Strength
| Tag | Meaning | In Practice |
|---|---|---|
| Strong Rec | Benefits clearly outweigh risks. | Standard practice. |
| Moderate Rec | Evidence favours benefit; some uncertainty. | Most patients should receive this. |
| Conditional Rec | Depends on individual circumstances. | Shared decision-making. |
| Against | No benefit or risks outweigh benefits. | Avoid. |
Evidence Quality
| Tag | Meaning | Confidence |
|---|---|---|
| High Evidence | Multiple RCTs or high-quality meta-analyses. | Very confident. |
| Moderate Evidence | Single RCT or large observational studies. | Reasonably confident. |
| Low Evidence | Expert consensus or small studies. | Best available guidance. |
For full classification systems, consult the original documents in References.